Zimmer must divest pipeline projects, IP rights, licenses and customer contracts to satisfy EU

By

Zimmer wins EU approval for $13.4 billion Biomet acquisition (press release)
(Reuters) - U.S. medical device maker Zimmer (ZMH.N) gained European Union regulatory approval on Monday for its proposed $13.4 billion purchase of rival Biomet [LVBHAB.UL] after agreeing to divest three businesses in Europe to allay competition concerns.
Zimmer, set to become the No. 2 player in the $45 billion global orthopedics market following the deal, will sell its knee implant unit and Biomet's elbow implant unit in Europe, as well as Biomet's knee implant brand in Denmark and Sweden.
The divestments include pi...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.